As BeiGene works to change its corporate identity and grow the reach of its cancer offerings around the globe, the company ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...

Neurology patient groups have chided the pharma industry for investing too little into treating disorders of the nervous ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Robert F. Kennedy Jr.'s nomination as the Trump administration's Department of Health and Human Services (HHS) secretary has ...

On the heels of the premiere of its first-ever Spanish-language Cologuard campaign, Exact Sciences is doubling down on its ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

After a labeling mix-up prompted a recall of a popular panic disorder drug this summer, Endo’s U.S. subsidiary is widening the scope of its product pull. | Endo USA is expanding its previous recall of ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Eli Lilly’s Omvoh is rapidly ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...